Atlas Completes Final Tranche of £16.9 Million Series B Fundraising

April 29, 2014

BATH, England, April 29, 2014 /PRNewswire/ –

Atlas Genetics Ltd (“Atlas” or the “Company”), the diagnostic company developing
ultra-rapid decentralized and point-of-care (POC) tests for a range of infectious
diseases, today announces that it has completed the final tranche of its GBP16.9m Series B

The investors in this Series B financing include Novartis Venture Funds, Consort
Medical plc, LSP (Life Sciences Partners), BB Biotech Ventures, Johnson & Johnson
Development Corporation, YFM Equity Partners and private investors.

The final tranche of the GBP16.9 million Series B investment will be used to complete
the transfer to manufacture of the Atlas io(TM) system and file for European approval of
the first test for Chlamydia. The io(TM) system is a highly novel molecular diagnostic
system for the ultra-rapid diagnosis of a broad range of infectious diseases including
Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs). It is
based on a patent-protected electrochemical sensor technology that combines speed and
accuracy, and removes any requirement for costly optical components.

In addition to deployment in hospital settings, the Atlas system will make it
possible, for the first time, to carry out infectious disease tests in primary care
clinics and GP surgeries that are as accurate as those carried out in hospital
laboratories. This will enable clinicians to test and commence treatment within the same
appointment and ensure much improved compliance, particularly in the area of STIs, where a
significant proportion of patients fail to return for test results or follow-on treatment.

Dr John Clarkson, Chief Executive Officer of Atlas, commented: “We have made
tremendous progress in the development of the io(TM) system since the initial Series B
investment in July 2011 and we look forward to gaining regulatory approval for our first
product, a Chlamydia test, around the end of this year.”

About Atlas (http://www.atlasgenetics.com)

Atlas (Atlas Genetics Ltd) develops ultra-rapid decentralized and point-of-care (POC)
diagnostic tests for infectious diseases. The Atlas io(TM) system uses patented technology
based on the use of a novel electrochemical sensor that combines speed, accuracy and
multiplex detection capability. The Company has its head office and laboratory facilities
near Bath. Atlas was established in 2005 and is financed by VC, corporate and private
investors including Novartis Venture Funds, Consort Medical plc, J&J Development
Corporation, Life Science Partners (LSP), BB Biotech Ventures and YFM Equity Partners.

Rapid and simple-to-use diagnostics offer health professionals the ability to test for
medical conditions at or close to the site of patient care. Atlas has developed a flexible
technology platform for decentralized and POC testing, which has been designed to
accurately and quickly diagnose a wide range of medical conditions within 30 minutes. The
Atlas io(TM) system consists of an inexpensive Reader into which a disposable cartridge
containing a patient sample is inserted. The system is scheduled for clinical trials in
2014, followed by rollout in Europe and the United States, pending regulatory approvals.

Atlas is developing tests for a range of infectious diseases including sexually
transmitted infections and hospital acquired infections. The Atlas io(TM) system will
initially be launched for the testing of Chlamydia and Gonorrhoea, allowing clinicians to
test and treat patients in a single visit. Over 50 million tests are carried out for these
diseases in Europe and the US every year. According to the European Centre for Disease
Prevention and Control, Chlamydia is the most frequently reported Sexually Transmitted
Infection, with prevalence rates in young people between 5-10%, whilst Gonorrhoea is the
second most commonly reported STI. The worldwide in vitro diagnostic market for infectious
disease testing is estimated to be worth around US$9 billion.

Contact details:

        Atlas Genetics Ltd:
        John Clarkson
        Tel: +44(0)1225-717930

        FTI Consulting:
        Mo Noonan / Ben Atwell / Natalie Garland-Collins
        Tel: +44(0)20-3727-1000

SOURCE FTI Consulting and Atlas Genetics Ltd

Source: PR Newswire

comments powered by Disqus